Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 2/2010

01.04.2010 | Research Article

A pilot study to compare natural health product–drug interactions in two databases in Canada

verfasst von: Guillaume Faubert, Denis Lebel, Jean-François Bussières

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Objective The aim of this article is to evaluate and compare two natural health product databases for the purpose of integrating them into a pharmacy information system in Canada. Methods This is a descriptive pilot study that compared the Natural Medicine Comprehensive Database® (NMCD) and Natural Standard® Database (NSD). We randomly chose five hospital patient files. For each drug prescription, we searched for and counted the number of potential natural health product–drug interactions in each database. Main outcome measure We compared all of the potential interactions between dexamethasone and the natural health products in both databases. We also evaluated the quality of a selection of references for 30 potential natural health product–dexamethasone interactions. Results Five pediatric patient files were selected for a total of 21 different common names. The number of potential natural health product–drug interactions identified varied from 12 (salbutamol-albuterol) to 129 (dexamethasone) in the NSD for an average of 63 ± 33. The number of potential natural health product–drug interactions identified varied from 1 (salbutamol-albuterol) to 96 (dexamethasone) in the NMCD for an average of 55 ± 27. There was no significant difference between the average number of potential natural health product–drug interactions between the databases (P = 0.40). The average number of common potential interactions was 9 ± 8. Thirty potential interactions of dexamethasone were compared. The number of abstracts per pair of interactions varied from 0 (Aloe-dexamethasone in the NSD) to 17 (dexamethasone-St. John’s wort in the NMCD). For the 10 pairs that were common to both databases, the number of abstracts given was 4.5 ± 4.7 for the NMCD and 3.1 ± 2.1 for the NSD (P = 0.41) and the average evaluation score was 4.6 ± 1.5 for the NMCD and 5.6 ± 1.2 for the NSD (P = 0.43). Conclusion This pilot study presents a comparison of potential natural health product–drug interactions from two different databases using two different scenarios in a hospital setting. The study reveals a high and variable number of pairs of natural health product–drug interactions per drug between the NSD and the NMCD. Further studies are necessary to evaluate the pertinence and hierarchy of the information offered by suppliers and natural health product databases.
Literatur
2.
Zurück zum Zitat Nestmann ER, Harwood M, Martyres S. An innovative model for regulating supplement products: natural health products in Canada. Toxicology. 2006;221:50–8.CrossRefPubMed Nestmann ER, Harwood M, Martyres S. An innovative model for regulating supplement products: natural health products in Canada. Toxicology. 2006;221:50–8.CrossRefPubMed
3.
Zurück zum Zitat Ohama H. Legal situation of supplements in the United States and European union. Yakugaku Zasshi. 2008;128:839–50.CrossRefPubMed Ohama H. Legal situation of supplements in the United States and European union. Yakugaku Zasshi. 2008;128:839–50.CrossRefPubMed
4.
Zurück zum Zitat Murty MP. ostmarket surveillance of natural health products in Canada: clinical and federal regulatory perspectives. Can J Physiol Pharmacol. 2007;85:952–5.CrossRefPubMed Murty MP. ostmarket surveillance of natural health products in Canada: clinical and federal regulatory perspectives. Can J Physiol Pharmacol. 2007;85:952–5.CrossRefPubMed
5.
Zurück zum Zitat Laeeque H, Boon H, Kachan N, Cohen JC, D’Cruz J. The Canadian Natural Health Products (NHP) regulations: industry perceptions and compliance factors. BMC Health Serv Res. 2006;6:63.CrossRefPubMed Laeeque H, Boon H, Kachan N, Cohen JC, D’Cruz J. The Canadian Natural Health Products (NHP) regulations: industry perceptions and compliance factors. BMC Health Serv Res. 2006;6:63.CrossRefPubMed
7.
Zurück zum Zitat Kelly JF, Kaufman DW, Kelley K, Rosenberg L, Anderson TE, Mitchell AA. Recent trends in use of herbal and other natural products. Arch Intern Med. 2005;165:281–6.CrossRefPubMed Kelly JF, Kaufman DW, Kelley K, Rosenberg L, Anderson TE, Mitchell AA. Recent trends in use of herbal and other natural products. Arch Intern Med. 2005;165:281–6.CrossRefPubMed
8.
Zurück zum Zitat Ansani NT, Ciliberto NC, Freedy T. Hospital policies regarding herbal medicines. Am J Health-Syst Pharm. 2003;60:367–70.PubMed Ansani NT, Ciliberto NC, Freedy T. Hospital policies regarding herbal medicines. Am J Health-Syst Pharm. 2003;60:367–70.PubMed
9.
Zurück zum Zitat Brubaker ML. Setting up the herbal formulary system for an alternative medicine clinic. Am J Health-Syst Pharm. 1998;55:435–6.PubMed Brubaker ML. Setting up the herbal formulary system for an alternative medicine clinic. Am J Health-Syst Pharm. 1998;55:435–6.PubMed
10.
Zurück zum Zitat Cook TF, Frighetto L, Marra CA, Jewesson PJ. Patterns of use and patients’ attitudes toward complementary medications: a survey of adult general medicine patients at a major Canadian teaching hospital. Can J Clin Pharmacol. 2002;9:183–9.PubMed Cook TF, Frighetto L, Marra CA, Jewesson PJ. Patterns of use and patients’ attitudes toward complementary medications: a survey of adult general medicine patients at a major Canadian teaching hospital. Can J Clin Pharmacol. 2002;9:183–9.PubMed
11.
Zurück zum Zitat Bazzie KL, Witmer DR, Pinto B, Bush C, Clark J, Deffenbaugh J. National survey of dietary supplement policies in acute care facilities. Am J Health-Syst Pharm. 2006;63:65–70.CrossRefPubMed Bazzie KL, Witmer DR, Pinto B, Bush C, Clark J, Deffenbaugh J. National survey of dietary supplement policies in acute care facilities. Am J Health-Syst Pharm. 2006;63:65–70.CrossRefPubMed
12.
Zurück zum Zitat De Smet PA, Floor-Schreudering A, Bouvy ML, Wensing M. Clinical risk management of interactions between natural products and drugs. Curr Drug Metab. 2008;9:1055–62.CrossRefPubMed De Smet PA, Floor-Schreudering A, Bouvy ML, Wensing M. Clinical risk management of interactions between natural products and drugs. Curr Drug Metab. 2008;9:1055–62.CrossRefPubMed
13.
Zurück zum Zitat Skalli S, Zaid A, Soulaymani R. Drug interactions with herbal medicines. Ther Drug Monit. 2007;29:679–86.CrossRefPubMed Skalli S, Zaid A, Soulaymani R. Drug interactions with herbal medicines. Ther Drug Monit. 2007;29:679–86.CrossRefPubMed
14.
Zurück zum Zitat Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, et al. Herb–drug interactions: a literature review. Drugs. 2005;65:1239–82.CrossRefPubMed Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, et al. Herb–drug interactions: a literature review. Drugs. 2005;65:1239–82.CrossRefPubMed
15.
Zurück zum Zitat Joshi R, Medhi B. Natural product and drugs interactions, its clinical implication in drug therapy management. Saudi Med J. 2008;29:333–9.PubMed Joshi R, Medhi B. Natural product and drugs interactions, its clinical implication in drug therapy management. Saudi Med J. 2008;29:333–9.PubMed
16.
Zurück zum Zitat Bent SH. Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center. J Gen Intern Med. 2008;23:854–9.CrossRefPubMed Bent SH. Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center. J Gen Intern Med. 2008;23:854–9.CrossRefPubMed
17.
Zurück zum Zitat Busse JW, Heaton G, Wu P, Wilson KR, Mills EJ. Disclosure of natural product use to primary care physicians: a cross-sectional survey of naturopathic clinic attendees. Mayo Clin Proc. 2005;80:616–23.CrossRefPubMed Busse JW, Heaton G, Wu P, Wilson KR, Mills EJ. Disclosure of natural product use to primary care physicians: a cross-sectional survey of naturopathic clinic attendees. Mayo Clin Proc. 2005;80:616–23.CrossRefPubMed
18.
Zurück zum Zitat Bailey DG, Dresser GK. Natural products and adverse drug interactions. CMAJ. 2004;170:1531–2.PubMed Bailey DG, Dresser GK. Natural products and adverse drug interactions. CMAJ. 2004;170:1531–2.PubMed
19.
Zurück zum Zitat Traynor K. Report urges scientific standards for alternative medicine. Am J Health-Syst Pharm. 2005;62:562–8.PubMed Traynor K. Report urges scientific standards for alternative medicine. Am J Health-Syst Pharm. 2005;62:562–8.PubMed
20.
Zurück zum Zitat Kroll DJ. ASHP statement on the use of dietary supplements. Am J Health-Syst Pharm. 2004;61:1707–11.PubMed Kroll DJ. ASHP statement on the use of dietary supplements. Am J Health-Syst Pharm. 2004;61:1707–11.PubMed
21.
Zurück zum Zitat Goldman RD, Rogovik AL, Lai D, Vohra S. Potential interactions of drug–natural health products and natural health products–natural health products among children. J Pediatr. 2008;152:521–6. 526.CrossRefPubMed Goldman RD, Rogovik AL, Lai D, Vohra S. Potential interactions of drug–natural health products and natural health products–natural health products among children. J Pediatr. 2008;152:521–6. 526.CrossRefPubMed
22.
Zurück zum Zitat Singh SR, Levine MA. Potential interactions between pharmaceuticals and natural health products in Canada. J Clin Pharmacol. 2007;47:249–58.CrossRefPubMed Singh SR, Levine MA. Potential interactions between pharmaceuticals and natural health products in Canada. J Clin Pharmacol. 2007;47:249–58.CrossRefPubMed
23.
Zurück zum Zitat Ulbricht C, Chao W, Costa D, Rusie-Seamon E, Weissner W, Woods J. Clinical evidence of herb–drug interactions: a systematic review by the natural standard research collaboration. Curr Drug Metab. 2008;9:1063–120.CrossRefPubMed Ulbricht C, Chao W, Costa D, Rusie-Seamon E, Weissner W, Woods J. Clinical evidence of herb–drug interactions: a systematic review by the natural standard research collaboration. Curr Drug Metab. 2008;9:1063–120.CrossRefPubMed
24.
Zurück zum Zitat Clauson KA, Polen HH, Peak AM, Marsh WA, DiScala SL. Clinical decision support tools: personal digital assistant versus online dietary supplement databases. Ann Pharmacother. 2008;42:1592–9.CrossRefPubMed Clauson KA, Polen HH, Peak AM, Marsh WA, DiScala SL. Clinical decision support tools: personal digital assistant versus online dietary supplement databases. Ann Pharmacother. 2008;42:1592–9.CrossRefPubMed
25.
Zurück zum Zitat Scott GN, Elmer GW. Update on natural product–drug interactions. Am J Health Syst Pharm. 2002;59:339–47.PubMed Scott GN, Elmer GW. Update on natural product–drug interactions. Am J Health Syst Pharm. 2002;59:339–47.PubMed
26.
Zurück zum Zitat Brulotte J, Vohra S. Epidemiology of NHP-drug interactions: identification and evaluation. Curr Drug Metab. 2008;9:1049–54.CrossRefPubMed Brulotte J, Vohra S. Epidemiology of NHP-drug interactions: identification and evaluation. Curr Drug Metab. 2008;9:1049–54.CrossRefPubMed
27.
Zurück zum Zitat Charrois TL, Hill RL, Vu D, Foster BC, Boon HS, Cramer K, et al. Community identification of natural health product–drug interactions. Ann Pharmacother. 2007;41:1124–9.CrossRefPubMed Charrois TL, Hill RL, Vu D, Foster BC, Boon HS, Cramer K, et al. Community identification of natural health product–drug interactions. Ann Pharmacother. 2007;41:1124–9.CrossRefPubMed
28.
Zurück zum Zitat Lebel D, Faubert G, Bussières JF. Intégration d’une base de données de produits de santé naturels à un progiciel pharmacie en établissement de santé. J Pharm Clin. 2009;28(2):103–7. Lebel D, Faubert G, Bussières JF. Intégration d’une base de données de produits de santé naturels à un progiciel pharmacie en établissement de santé. J Pharm Clin. 2009;28(2):103–7.
Metadaten
Titel
A pilot study to compare natural health product–drug interactions in two databases in Canada
verfasst von
Guillaume Faubert
Denis Lebel
Jean-François Bussières
Publikationsdatum
01.04.2010
Verlag
Springer Netherlands
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 2/2010
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-010-9364-2

Weitere Artikel der Ausgabe 2/2010

International Journal of Clinical Pharmacy 2/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.